Search Results

Your search for Chase Doyle and Caroline Helwick matches 2 pages

Showing 1 - 2

By Chase Doyle and Caroline Helwick / November 25, 2015

Expert Point of View: Clifford Hudis, MD, Shanu Modi, MD, and Richard Gelber, PhD

Discussant Clifford Hudis, MD, Chief of Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York, highlighted neratinib’s benefits while also advocating caution in interpreting the results due to incomplete data, the serious side effect of diarrhea, and the potentially...

breast cancer

By Chase Doyle and Caroline Helwick / November 25, 2015

Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer

Patients with early-stage HER2-positive breast cancer who received neratinib as extended adjuvant therapy demonstrated improved invasive disease–free survival, with an absolute benefit of 2.3% at 2 years.1 However, these results of the ExteNET trial, previously presented at the 2015 ASCO Annual...

Dec

Today In Oncology

Search Results

Your search for Chase Doyle and Caroline Helwick matches 2 pages

Expert Point of View: Clifford Hudis, MD, Shanu Modi, MD, and Richard Gelber, PhD

Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer

Phase I Trial Investigates HER-Targeted CAR-M for HER2-Overexpressing Solid Tumors

FDA Approves Triplet Therapy for Previously Treated Patients With Relapsed or Refractory Multiple Myeloma

Long-Term Follow-up of monarchE Benefit of Abemaciclib Plus Endocrine Therapy Maintained in Early High-Risk Breast Cancer

Immunotherapy Followed by Targeted Therapy Yields Greater Overall Survival in Patients With BRAF V600–Mutated Advanced Melanoma

Digital Symptom Monitoring System May Improve Patients’ Symptom Control and Physical Function During Cancer Therapy